A sporadic case of pseudohypoparathyroidism type Ib  by Morgado, Joana et al.
CA
J
a
b
c
a
A
R
A
K
P
G
M
P
P
G
M
I
n
p
h
w
ﬁ
t
1
lRev Port Endocrinol Diabetes Metab. 2016;11(2):212–214
www.elsev ier .p t / rpedm
Revista  Portuguesa
de  Endocrinologia,  Diabetes  e  Metabolismo
linical  case
 sporadic  case  of  pseudohypoparathyroidism  type  Ib
oana  Morgadoa,∗,  Patrícia  Diasb, Maria  de  Lurdes  Sampaioc, Ana  Berta  Sousab
Pediatrics Department, Hospital Espírito Santo de Évora E.P.E., Évora, Portugal
Genetics Department, Hospital Santa Maria, CHLN E.P.E., Centro Académico de Lisboa, Lisboa, Portugal
Pediatric Endocrinology Department, Hospital Santa Maria, CHLN E.P.E., Centro Académico de Lisboa, Lisboa, Portugal
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 17 September 2015
ccepted 22 February 2016
eywords:
seudohypoparathyroidism
NAS
ethylation
a  b  s  t  r  a  c  t
Introduction:  Pseudohypoparathyroidism  is  a genetically  heterogeneous  condition  characterized  by
hypocalcemia  and  hyperphosphatemia  resulting  from  end-organ  resistance  to  parathyroid  hormone
(PTH).  It is classiﬁed  into  several  distinct  entities  (type  Ia,  Ib, Ic,  type  II), according  to the  molecular
causes  and  clinical  features  of the  patients.
Case  report:  We  report  a symptomatic  case  of  a pediatric  patient  with  hypocalcaemia,  hyperphos-
phatemia,  hypomagnesaemia  and  an  elevated  serum  PTH  level  that  presented  with  tetany.  The  molecular
genetic  test  revealed  a GNAS  gene  methylation  defect  of  the A/B  promoter,  which  conﬁrms  the  diagnosis
of  a sporadic  form  of  pseudohypoparathyroidism  type  Ib.
© 2016  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
Espan˜a,  S.L.U.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Um  caso  de  pseudohipoparatiroidismo  tipo  Ib  esporádico
alavras-chave:
seudohipoparatiroidismo
NAS
etilac¸ ão
r  e  s  u  m  o
Introduc¸ ão:  o  pseudohipoparatiroidismo  é uma  doenc¸ a geneticamente  heterogénea  que se caracteriza  por
hipocalcemia  e  hiperfosfatemia  que  têm  origem  numa  resistência  periférica  dos  órgãos-alvo  a  hormona
paratiroideia  (PTH).  Classiﬁca-se  em  várias  entidades  distintas  (tipo  Ia, Ib,  Ic  e tipo  II) de  acordo  com  a
etiologia  molecular  e características  clínicas  dos  doentes.
Caso  clínico:  os autores  descrevem  o caso  de  uma crianc¸ a com  hipocalcemia,  hiperfosfatemia,  hipomag-
nesemia  e elevac¸ ão  da  PTH  sérica  que se  manifestou  através  de  tetania.  O estudo  molecular  revelou  um
defeito de  metilac¸ ão no promoter  A/B  do gene  GNAS  que  conﬁrmou  o diagnóstico  de  uma forma  esporádica
de  pseudohipoparatiroidismo  tipo  Ib.
©  2016  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e  Metabolismo.  Publicado  por Elsevier
Espan˜a,  S.L.U.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸ a  CC  BY-NC-ND  (http://creativecommons.ntroduction
Pseudohypoparathyroidism (PHP) is a genetically heteroge-
eous condition characterized by hypocalcemia and hyperphos-
hatemia resulting from end-organ resistance to parathyroid
ormone (PTH).1 Patients with this condition carry mutations
ithin the GNAS locus on chromosome 20q13.3.2,3 PHP is classi-
ed into several distinct entities (type Ia, Ib, Ic, type II), according
o the molecular causes and clinical features of the patients.4
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The GNAS gene is paternally imprinted in the proximal renal
tubules in humans. PHP-Ib is caused by defects of the maternally
derived GNAS allele and patients show hypomethylation at one or
more of the 4 differentially methylated regions (DMRs) of GNAS.
PHP-Ib can follow an autosomal dominant trait (AD-PHP-Ib) or
occur as a disorder that appears to be sporadic.5–7 Genetic causes
of PHP-Ib include cryptic deletions within the genes neighboring
GNAS, STX16 and NESP55, and epimutation of GNAS DMRs.5,8 A
few of the sporadic patients, all with broad methylation changes,
were shown to be affected by paternal uniparental isodisomy
(patUPD20) involving the long arm of chromosome 20, which com-
prises the GNAS locus,9–11 but most apparently sporadic cases have
not yet been resolved at the molecular level5,8,12–16 raising the
ished  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND
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oFig. 1. CT scan showing bilateral, symmetric calciﬁcations in thalamu
uestion as to whether alternative mechanisms could explain the
ethylation changes observed in sporadic PHP-Ib patients such as
nvironmental and exogenous factors.17–20
PHP-Ib patients present with PTH- and, sometimes, TSH-
esistance and typically lack the features of Albright hereditary
steodystrophy (AHO), although some PHP-Ib cases with
NAS imprinting defects have recently been shown to have
HO features.21–24 These patients are usually identiﬁed by
ypocalcemia-associated neuromuscular irritability, such as
etany, generalized convulsions, and/or muscle cramps, although a
ubstantial fraction of the patients remain asymptomatic and are
dentiﬁed only by familial studies.6,25
Here, we report a Portuguese patient with sporadic PHP-Ib due
o promoter A/B methylation defect with homozygous abnormality.
ase report
This female patient was born as the ﬁrst child to nonconsan-
uineous parents from Guinea-Bissau at 41 weeks of gestation after
n uncomplicated pregnancy and delivery. Her birth weight was
550 g (95th percentile), length 55 cm (95th percentile) and head
ircumference 36.5 cm (83rd percentile). She developed neonatal
ypoglycemia immediately after birth and hyperbilirrubinemia on
he 3rd day of life. Neonatal screening tests were normal and her
ostnatal growth evolved on the 95th percentile with no develop-
ental delay.
In December 2002, at the age of nine she was admitted to the
ospital due to tetany, which was wrongly interpreted as a gener-
lized seizure. There was a history of general fatigue, poor school
erformance and tingling in the hands that began 2 months ear-
ier. Physical examination showed truncal obesity, round face but
o other phenotypic features of AHO. Her height was 143 cm (93rd
ercentile). Laboratory investigation revealed serum hypocalcemia
ith a calcium level of 5.6 mg/dL (normal range 9.6–10.6 mg/dL),
yperphosphatemia, hypomagnesaemia and an elevated serum
TH level of 165 pg/mL (normal range 10–60 pg/mL), normal alka-
ine phosphatase, serum albumin and a normal thyroid function.
ead computerized tomography revealed bilateral, symmetric
alciﬁcations in thalamus, basal ganglia and white subcortical fron-
otemporal substance (Fig. 1).
She was treated with oral calcium and calcitriol and her general
atigue markedly improved.
Her mother and younger sister did not show clinical or labora-
ory evidence suggestive of an abnormal regulation of calcium and
hosphate homeostasis.
She was referred to a geneticist for further evaluation. After
btaining written informed consent, genomic DNA was  extractedal ganglia and white subcortical frontotemporal substance (arrows).
from leukocytes of our patient by standard methods. Methylation
analysis of the promoter regions of the splice variants XL˛s and A/B
was performed by bisulﬁte sequencing.26 The molecular genetic
result revealed a GNAS gene methylation defect of the A/B pro-
moter, which is speciﬁc for PHP type Ib. The STX16 deletion was
not detectable in the patient.
At her follow-up, at the age of 17 the patient remained without
symptoms, having normal puberty, height 173 cm (94th per-
centile) and obesity with a BMI  of 31.24 kg/m2. Currently her
regimen consists of both calcitriol and calcium supplements with
poor adherence to treatment. Her serum calcium levels have
ranged from 6.4 to 8.0 mg/dL (normal range 9.6–10.6 mg/dL) with
phosphorous levels varying from 6.8 to 7.3 mg/dL (normal range
3.1–4.7 mg/dL) and PTH levels above the normal range. Her urinary
calcium to creatinine ratios have been normal. She has had no fur-
ther episodes of tetany and has shown both clinical and biochemical
improvement.
At the age of 18 she became pregnant. At 32 weeks of pregnancy
she was  hospitalized for vaginal bleed, was  treated with oral iron
and rest was  advised. The delivery, at 38 weeks, was uneventful.
Her asymptomatic son was also referred to a geneticist and the
molecular genetic test performed at the age of 7 months did not
conﬁrm the diagnosis of PHP type Ib.
Discussion
In this report, we describe laboratory, epigenetic, and genetic
ﬁndings in a patient, who  presented with tetany, hypocalcemia,
hyperphosphatemia, hypomagnesaemia and an elevated serum
PTH level at the age of nine. Although the initial clinical onset
of PHP-Ib may  be due to a severe hypocalcaemia leading to neu-
romuscular irritability, such as tetany or generalized convulsions,
the hypocalcaemic condition may  become clinically evident only
during the pubertal growth spurt, when calcium requirements are
higher. Another important factor to be considered is the seasonal
period. It is usually during autumn or winter, when the sun expo-
sure is lower, that the 25-hydroxyvitamin D reaches the lowest
blood concentration that might lead to hypocalcaemia, which is
consistent with the time of presentation of our patient. Another
possible explanation for the late detection of hypocalcaemia might
be a delayed onset of parathyroid hormone-resistance due a grad-
ual development of paternal Gs-alpha silencing in target tissues.27
The combination of high PTH and low serum calcium led to the
suspicion of end organ resistance to PTH. The mild features of AHO
phenotype favored the diagnosis of PHP-Ia although her physical
examination was not positive for short stature, heterotopic ossiﬁ-
cations or mental retardation. Some PHP-Ib cases described have
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een shown to have some AHO features.21,23 Molecular character-
zation is currently a reliable method to differentiate the various
ubtypes of PHP. The diagnosis of PHP-Ib in our patient was  con-
rmed by methylation analysis of the promoter regions of the splice
ariants XL˛s and A/B, which revealed a GNAS gene methylation
efect. The STX16 deletion was not detectable in the patient and a
poradic form of PHP-Ib was conﬁrmed.
Her healthy mother and younger sister were not tested for the
enetic defect. PHP-Ib is transmitted only from the mother and her
on’s molecular genetic test was negative for the condition. The
ecision to request the genetic test despite our patient’s sporadic
orm was based on the fact that the identiﬁcation of this rare disease
llows an early diagnosis, and may  prevent hypocalcemia-related
ife-threatening complications.
The aim of PHP therapy is to obtain an adequate calcium-
hosphate control and to correct the multiple hormonal resis-
ances, when present. The goal is to maintain blood calcium
etween 8.8 and 10.8 mg/dL, and the urinary calcium/urinary creat-
nine ratio <0.228 which was not the case in our patient due to poor
reatment adherence. It is crucial to emphasize the importance of
reatment adherence that may  prevent further symptoms.
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